breast-cancer

Documents about breast-cancer

• A Deep Learning Breast Cancer Risk Model for Precise Supplemental Screening.#156874NCBI PubMed Central
• Machine learning enhanced optical spectroscopy for breast cancer diagnosis: A review.#161900NCBI PubMed Central
• Cancer Detection in Breast MRI Screening via Explainable AI Anomaly Detection.#221194NCBI PubMed Central
• Natural G-Quadruplex Stabilizers: A Targeted Strategy for Breast Cancer Therapy.#244276NCBI PubMed Central
• Addressing Domestic Abuse Among Couples Experiencing Breast or Gynecologic Cancer in Africa.#247526NCBI PubMed Central
• Stratification and therapeutic potential of PML in metastatic breast cancer#330391Infoscience
• Genetic regulatory axis between AGR2 and ESR1 promotes breast cancer progression.#334974NCBI PubMed Central
• TabSurv: Tabular Foundation Model for Breast Cancer Prognosis using Gene Expression Data#337067bioRxiv / medRxiv
• Biomarker identification of triple negative breast cancer subtypes using machine learning.#342502NCBI PubMed Central
• Metabolic phenotypes of doxorubicin-induced cardiotoxicity among patients with breast cancer.#345199NCBI PubMed Central
• The influence of locus of control, coping strategies and time perspective on post-traumatic growth in survivors with primary breast cancer#172964HAL (France)
• Figure 1 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246353Figshare
• Figure 2 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246354Figshare
• Figure 3 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246355Figshare
• Figure 4 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246356Figshare
• Figure 5 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246357Figshare
• Figure 6 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246358Figshare
• Role of Multi-modality Imaging in the Assessment of Chemotherapy Related Cardiac Dysfunction Among Cancer Patients#28296ClinicalTrials.gov
• Qualificação do manual "Câncer de Mama : orientações para pacientes e familiares"#215519Lume 5.8
• Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of ER+ breast cancer brain metastases in young and aged hosts#238027bioRxiv / medRxiv
• EpCAM CAR-T for Treatment of Advanced Solid Tumors#245488ClinicalTrials.gov
• Role of genetic variations of parp1 polymorphisms on triple negative breast cancer (TNBC) susceptibility risk#279008USM Repository
• Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases#283217ClinicalTrials.gov
• Machine learning models based on magnetic resonance imaging for predicting Lymphovascular Invasion in Invasive Breast Cancer#242886PLOS
• Assessment of risk factors of breast cancer among women in Dodoma, Tanzania: a community-based cross-sectional study.#9924PubMed
• Prevalence and associated factors of kinesiophobia in postoperative patients with breast cancer: A systematic review and meta-analysis#253502Europe PMC
• Comparative Effectiveness Of Digital Breast Tomosynthesis And Digital Mammography In Detecting Invasive Lobular Carcinoma And Smaller Tumors Among Older Women#286858EliScholar
• Association of Pembrolizumab Infusion Time and Efficacy in Patients With Non-metastatic Triple-negative Breast Cancer (TNBC) Treated With Neoadjuvant Chemotherapy and Immunotherapy#307439ClinicalTrials.gov
• Supplementary Figure S1 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246359Figshare
• Supplementary Figure S2 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246360Figshare
• Supplementary Figure S3 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246361Figshare
• Supplementary Figure S4 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246362Figshare
• Supplementary Figure S5 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246363Figshare
• Supplementary Figure S6 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246364Figshare
• Supplementary Figure S7 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246365Figshare
• Supplementary Figure S8 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246366Figshare
• Supplementary Table 1 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246367Figshare
• Supplementary Table 2 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246368Figshare
• <b><i>ESR1 </i></b><b>and </b><b><i>PIK3CA</i></b><b> Polymorphisms as Potential Genetic Susceptibility Markers for Breast Cancer Risk in Bangladeshi Women: A Case-Control Study</b>#337313Figshare
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer#148580ClinicalTrials.gov
• A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies#353286ClinicalTrials.gov
• National Awareness and Early Diagnosis Initiative: Cancer Awareness Measure, Brighton and Hove, 2010#207770UK Data Service OAI-PMH Repository (Production)
• Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer#287530ClinicalTrials.gov
• Post-treatment adaptation experiences of women breast cancer survivors: a qualitative study.#30813NCBI PubMed Central
• iPSC-derived breast cancer models: advancing the study of BRCA1-driven tumorigenesis.#138435NCBI PubMed Central
• Exploring Gallium(III) Complexes as Emerging Therapeutic Candidates for Breast Cancer.#145990NCBI PubMed Central
• Challenges and strategies for delivering effective breast cancer care in conflict zones.#148207NCBI PubMed Central
• Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy#154643ClinicalTrials.gov
• Artificial Intelligence in the Management of Breast Cancer: A Comprehensive Review.#172004NCBI PubMed Central
• Leveraging AI chatbots in supporting breast and ovarian cancer patients: A scoping review.#182489NCBI PubMed Central